The Future of Weight Management

The Journal published Phase III clinical trial results of Eli Lilly’s weight-loss drug, tirzepatide. If the drug name rings a bell, it’s because I discussed the preliminary results a couple of weeks ago. At the time, I emphasized these initial results were a big deal. This time, I’m emphasizing these final results are a huge deal that has implications for solving the metabolic…

Read More

Healthcare Supply Chain Gone Haywire

SUPPLY CHAIN Healthcare Supply Chain Gone Haywire Hospitals are grappling with yet another serious, pandemic-induced supply chain shortage. This time: intravenous contrast. My ThoughtsGE Healthcare’s production site in Shanghai shut down in April after the city went into another Covid-19 lockdown. Return to production has been slow. The company estimates the site is now operating at…

Read More

The Other Epidemic

PUBLIC HEALTH The Other Epidemic By the time you finish reading this newsletter, at least one American will have died from an opioid overdose. Overdose deaths have increased nearly 50% since the pandemic began, according to new data from the CDC. 2021 alone saw a record 108K overdose deaths, likely driven by fentanyl-laced drugs.  The DeetsWhile the…

Read More

The Next Frontier of Migraine

Fresh off a profitable fiscal year, Pfizer will use its cash to acquire Biohaven Pharmaceuticals for $11.6B—their largest acquisition since 2016. Biohaven focuses on neurological and neuropsychiatric diseases like migraines, which are often overlooked and untapped in therapeutics. The DeetsThe $11.6B deal will give Pfizer access to Biohaven’s innovative calcitonin gene-related peptide (CGRP)-targeting migraine medications: Rimegepant (Nurtec): FDA-approved for prevention and…

Read More

Medicare Disadvantage?

Some Medicare Advantage health plans have wrongfully denied or delayed prior authorizations and payment requests, according to a new report from the Office of the Inspector General. Are these MA plans genuinely “great” if they only burden patients and providers? Some Background The $412 billion MA market is booming. MA plans saw an 8.8% increase in enrollment this year,…

Read More

Medicare Disadvantage?

INSURANCE  Medicare Disadvantage? Some Medicare Advantage health plans have wrongfully denied or delayed prior authorizations and payment requests, according to a new report from the Office of the Inspector General. Are these MA plans genuinely “great” if they only burden patients and providers? Some BackgroundThe $412 billion MA market is booming. MA plans saw an 8.8% increase in enrollment…

Read More